Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

NCT03357939 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune System Disorder

Interventions

DRUG: HLX03
DRUG: adalimumab

Sponsor

Shanghai Henlius Biotech